| Autor: |
Fernando Bessone, Nelia Hernandez, Raymundo Parana, Manuel Mendizabal, Adriana Sanchez, Vinicius Nunes, Ezequiel Ridruejo, Daniela Schiodi, Genario Santos, Eduardo Fassio, Schinoni Maria I., Hugo Tanno, Martin Tagle, Pedro Montes, Marco Arrese, Nahum Mendez-Sanchez, Javier Brahm, Marcos Girala, Isabel Lizarzábal M., Edgardo Mengual, Enrique Carrera, Fernando Contreras, Inmaculada Medina-Caliz, Mercedes Robles-Díaz, Aida Ortega-Alonso, Miren García-Cortes, Ismael Alvarez-Alvarez, Hao Niu, Elvira Bonilla, Isabel Lucena M., Andrade Raul J. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology, Vol 24, Iss , Pp 100515- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1665-2681 |
| DOI: |
10.1016/j.aohep.2021.100515 |
| Popis: |
Introduction: In 2011, the Latin-American DILI-Network (LATINDILIN) set up under the guidance of the Spanish DILI Registry a network of hepatologists to prospectively identify and characterize DILI patients. Aim: To evaluate the drugs more frequently associated with DILI in LA, clinical phenotype and outcome. Methods: Demographics, clinical and biochemical parameters of all cases included in the LATINDILI Network were analysed according to the type of liver injury (hepatocellular, Hep; cholestatic, Chol and mixed, Mix). Results: 404 DILI cases were included. Anti-infectives (31%), musculoskeletal system drugs (13%) and herbal products (9.2%) were the main causative therapeutic drug classes. Mean age was 49 years (female sex, 61%). Hep injury predominated (62%) whereas Chol and Mix patterns were 24% and 15% of cases, respectively. Chol patients (mean age 56y) were older than Hep and Mix cases (47 and 50, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
